Amicus Briefs
When a court considers a case whose outcome may affect consumers or competition, the FTC may file a “friend of the court” brief to provide information that can help the court make its decision in a way that protects consumers or promotes competition. To find a specific FTC brief, use the filters on this page.
Displaying 81 - 100 of 132Pages
Spano v. SAFECO Insurance Co
Cleveland Bar Ass’n v. Compmanagement, Inc
Andrx Pharmaceuticals, Inc. v. Kroger Co
Joint brief of the United States and the Federal Trade Commission, urging the Court to deny a writ of certiorari in this case, regarding private patent litigation and the legal standards applicable to “reverse payment” patent litigation settlements in the Hatch-Waxman context.
Jackson, Tennessee Hospital Co. v. West Tennessee Healthcare, Inc
Cole v. U.S. Capital, Inc. et al.
Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc.
The Commission argues that the district court erred by dismissing Teva's complaint against Pfizer in this Hatch-Waxman Act case. Teva sought a declaratory judgment that its generic version of sertraline hydrochloride would not infringe a patent held by Pfizer (or that the patent was invalid). The brief argues that the court applied the wrong test to assess jurisdiction. It failed to take account of the fact that, unless Teva can obtain a court decision regarding Pfizer's patent, the FDA cannot give Teva approval to market its generic drug until 180 days after the first generic applicant (Ivax Pharmaceuticals) enters the market with its version. The brief also explains that the district court’s holding will leave subsequent generic applicants (such as Teva) powerless to prevent brand-name manufacturers and first generic applicants from greatly delaying other generic manufacturers from entering the market.
Allen and Sharon Schneider v. Citicorp Mortgage, Inc. and Citicorp
Amicus brief objecting to a proposed settlement that called for consumers to be compensated with coupons for $100 off their next new mortgage or refinancing within the next two years in a case involving allegations that Citicorp violated the Real Estate Settlement Procedures Act. The FTC argued it is extremely doubtful that the case satisfied the legal requirements for class certification, that the coupons were worth much less than their face value, and that the proposed counsel fee appears excessive in light of the likely low value of the settlement.
Willes v. State Farm Fire and Casualty Co
F. Hoffmann-La Roche Ltd., et al. v. Empagran S.A.
Rausch v. The Hartford Financial Services Group, Inc.
Brentwood Academy v. Tennessee Secondary School Athletic Ass’n
Pruitt v. Kaufman and Broad Home Corp. et al.
On Review of UPL Advisory Opinion
Haese v. H & R Block, Inc.,
Dee-K Enterprises, Inc. v. Heveafil Sdn. Bhd.
Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP
Empagran S.A. v. F. Hoffmann-LaRoche, Ltd.
SmithKline Beecham Corp. v. Apotex Corp.
Memorandum of the Federal Trade Commission, as amicus curiae, addressing the propriety of de-listing a patent from FDA's "Orange Book," as a remedy for patent invalidity. The brief explains that improperly-maintained Orange Book listings may serve as a barrier to competition, and that there may be substantial consumer benefits to a de-listing remedy.